Home » News » 12/05 » Sankyo Pharma and Stada Arzneimittel in 82m euro deal

Sankyo Pharma and Stada Arzneimittel in 82m euro deal

Date published: 13/12/2005

Stada Arzneimittel has signed an agreement with Sankyo Pharma to buy a package of 11 European branded products for €82 million. The products last year achieved European-wide sales of around €38 million and include Mobilat and Hirudoid, which have sales of €18 million and €14 million respectively.

The products are mainly sold in Germany, Italy, the UK and Belgium and in these countries, they will be, following the transfer of the drug approvals to the individual Stada sales companies, directly integrated into the existing Stada sales structures.

Takeover of the various approvals and trademarks will be staggered until April 2007 and Stada will take over sales responsibility for the products in the individual national markets as soon as the drug approvals have been transferred.

Stada has stated that it believes despite the staggering of takeovers the company will "draw economic benefit from the entire product package from the time the agreements are signed."

© Adfero Ltd

Disclaimer

AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.